Oncology Central

Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma


Given the high morbidity and mortality associated with metastatic melanoma, considerable attention has been paid to identifying potential therapies. Until recently, few therapies have been specifically approved for treating metastatic melanoma. In an attempt to increase clinical trial successes, many therapies are implementing biomarkers for patient stratification.

To view restricted content, please:

Leave A Comment